Japan news from FiercePharma
News
Teva seeks venture partner in Japan
Fresh off its $7.5 billion deal to buy Barr Pharmaceuticals, Teva is eyeing joint ventures in Japan. CEO Shlomo Yanai told the Financial Times that establishing a beachhead in that country is a top Read more...
Roche warns of Tamiflu psych effects
After some arm-twisting from the FDA, Roche has added stronger warnings to its Tamiflu label. In a Dear Healthcare Professional letter, the company cautioned doctors about the sometimes-fatal Read more...
Japan changes scrips to favor generics
The tidal wave of generics has reached Japan. That country's government has proposed changes to prescription forms that would promote use of cheaper generics. Japanese copycat-drug companies saw Read more...
SPOTLIGHT: Merck KGaA leads team to sell Erbitux in Japan
Merck KGaA leads team to sell Erbitux in Japan Call it a trifecta: ImClone Systems, Bristol-Myers Squibb and Merck KGaA are joining together to develop and market ImClone's cancer drug Erbitux in Read more...
It's Merck v. Glaxo in vaccine battle
Call it the battle of the HPV vaccines. For the past week, either Merck's Gardasil or GlaxoSmithKline's Cervarix--or both--have captured headlines: • Glaxo submits Cervarix for approval in Japan Read more...
Pfizer plots spinoff of Japanese R&D
Saved by the spinoff. Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. The company Read more...
Get more Japan coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets